Optimal PSA Threshold for Obtaining MRI-Fusion Biopsy in Biopsy-Naïve Patients

Table 1

Clinicopathologic characteristics of the cohort.

Characteristics-continuous	Mean (SD)
Age (years)	64.5 (7.4)
MRI prostate volume (grams)	53.2 (24.5)
	Median (IQR)
PSA (ng/mL)	6.5 (4.8–8.6)
Characteristics-categorical	No.	%
Race/ethnicity
White	239	91.9
Black	13	5.0
Hispanic	3	1.5
Asian/Pacific Islander	1	1.6
Location of lesions
Peripheral	127	48.8
Transitional	62	23.8
Peripheral + transitional	48	18.5
Central	11	4.2
AFS	2	0.8
Peripheral + central	8	3.1
Peripheral + AFS	1	0.4
Transitional + central	1	0.4
MRI number of lesions
1	147	56.5
2	74	28.5
3	31	11.9
4	8	3.1
Highest PI-RADS score
2	1	0.4
3	77	29.6
4	109	41.9
5	73	28.1
MRI EPE
No	224	86.2
Yes	36	13.8
MRI SVI
No	252	96.9
Yes	8	3.1
Highest Gleason group on fusion
0	101	38.8
1	9	3.5
2	77	29.6
3	24	9.2
4	14	5.4
5	35	13.5
Highest Gleason group on standard
0	110	42.3
1	26	10.0
2	61	23.5
3	21	8.1
4	15	5.8
5	27	10.4

SD = standard deviation; IQR = interquartile range; ng = nanograms; mL = milliliter; MRI = magnetic resonance imaging; PSA = prostate-specific antigen; PSAV = prostate-specific antigen velocity; AFS = anterior fibromuscular stroma; PI-RADS = Prostate Imaging Reporting and Data System; EPE = extraprostatic extension; SVI = seminal vesicle invasion.